The clinical significance of GIST FGL2 expression was investigated in two large GIST patient series using immunohistochemistry, the western Sweden series patient population of whom none received adjuvant imatinib after surgery, and the SSGXVIII clinical trial series. The gene discussed is FGL2; the disease is gastrointestinal stromal tumor.